As of 2024-12-12, the Intrinsic Value of Vertex Pharmaceuticals Inc (VRTX) is
439.08 USD. This Vertex valuation is based on the model Discounted Cash Flows (Growth Exit 5Y).
With the current market price of 468.29 USD, the upside of Vertex Pharmaceuticals Inc is
-6.20%.
The range of the Intrinsic Value is 314.37 - 786.86 USD
439.08 USD
Intrinsic Value
Vertex Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
314.37 - 786.86 |
439.08 |
-6.2% |
| DCF (Growth 10y) |
383.86 - 914.88 |
524.92 |
12.1% |
| DCF (EBITDA 5y) |
376.59 - 481.53 |
394.90 |
-15.7% |
| DCF (EBITDA 10y) |
433.77 - 575.18 |
468.35 |
0.0% |
| Fair Value |
-46.10 - -46.10 |
-46.10 |
-109.84% |
| P/E |
(41.03) - 637.30 |
212.57 |
-54.6% |
| EV/EBITDA |
293.50 - 649.99 |
383.44 |
-18.1% |
| EPV |
158.62 - 193.93 |
176.27 |
-62.4% |
| DDM - Stable |
(21.49) - (76.78) |
(49.13) |
-110.5% |
| DDM - Multi |
285.82 - 788.59 |
418.91 |
-10.5% |
Vertex Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
120,598.73 |
| Beta |
1.30 |
| Outstanding shares (mil) |
257.53 |
| Enterprise Value (mil) |
114,188.23 |
| Market risk premium |
4.60% |
| Cost of Equity |
8.13% |
| Cost of Debt |
6.95% |
| WACC |
8.12% |